Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibits 99.1 Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark Ten of 47 patients re

Event · Earnings
Original reporting
Published Nov 16, 2026, 1:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$APVO
Bullish
high confidence
Mentioned
$APVO
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$APVOBullishMed
01

Why it matters

The disclosed 79% remission rate in high‑risk TP53‑mutated AML and progress toward Phase 2 suggest significant clinical upside, likely prompting short‑term buying interest.

02

Market read

First public disclosure of strong early‑stage AML data and new capital raise; could move APVO stock and influence peer biotech valuations.

03

What to watch

Financing remains modest; cash runway is limited, and next regulatory milestones are still a year away.

Relevance 8/10Novelty 8/10Timing: today
AlphAI · Earnings readAPVO · Q3 2026 · ended 2026-09-30

Aptevo reports Q3 2026 net loss of $6.5 million and cash of $8.3 million, alongside mipletamig clinical updates and a $4.5 million warrant inducement and private placement

→Mixed quarter

The filing shows a lower net loss than the prior-year quarter and reports clinical updates for mipletamig, but cash fell from $9.8 million to $8.3 million over the quarter, and the August 2026 financing generated approximately $4.1 million net. The release does not report revenue, operating expenses, cash runway or guidance, so the financial read is limited.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net loss, third quarter 2026other$6.5M––
Cash and cash equivalents, as of September 30, 2026other$8.3M––
Gross proceeds, August 2026 warrant inducement and private placementotherapproximately $4.5 million––
Net proceeds, August 2026 warrant inducement and private placementotherapproximately $4.1 million––
Issuance costs, August 2026 warrant inducement and private placementother$400K––
Mipletamig complete remission and complete remission with incomplete hematologic recovery (CR/CRi) rate in evaluable TP53-mutated AML patients on mipletamig tripletother79%––
Evaluable frontline patients treated with mipletamig with venetoclax and azacitidine who proceeded to allogeneic stem cell transplantationotherten of 47––

What drove it

  • The release describes the August 2026 warrant inducement and private placement as providing additional capital for mipletamig and the next-generation pipeline.
  • The release reports a 79% CR/CRi rate in 14 evaluable TP53-mutated patients treated with mipletamig with venetoclax and azacitidine, against a published 41% composite remission rate for venetoclax plus azacitidine alone, as cited by the company from Pollyea DA, et al. (2022).
  • The company reports that ten of 47 evaluable frontline patients proceeded to allogeneic stem cell transplantation, and that refinements to the priming-dose regimen significantly reduced infusion-related reactions, in the company's words.

Concerns

  • Cash and cash equivalents declined from $9.8 million at June 30, 2026 to $8.3 million at September 30, 2026.
  • The release does not state a cash runway, operating expense figures or quarterly cash burn, so the period-end cash balance cannot be assessed against spending in this document.
  • The up to $22.5 million from new warrants depends on future exercise at $4.03 per share, which the release does not describe as assured.
  • The release is based on a small clinical sample: 14 evaluable TP53-mutated patients for the 79% rate and 47 evaluable frontline patients for the transplant count. The forward-looking statements section cautions that interim data may differ from later trials.

What to watch

  • RAINIER Phase 1b dose optimization completion, targeted by year-end 2026, per the release.
  • Regulatory interaction for mipletamig, planned for the first half of 2027, per the release.
  • Exercise of the new warrants covering up to 5,583,150 shares at $4.03 per share.
  • Cash and cash equivalents in the next filing, against the $8.3 million reported at September 30, 2026.
  • Timing of IND-enabling studies for APVO451 and the Niowave-linked radiopharmaceutical program, which the release expects in 2027.

Balance sheet and cash flow

  • Cash and cash equivalents were $8.3 million as of September 30, 2026, compared with $9.8 million as of June 30, 2026.
  • In August 2026, the company completed a warrant inducement and private placement that generated gross proceeds of approximately $4.5 million, or approximately $4.1 million net of $0.4 million in issuance costs.
  • Existing warrant holders exercised warrants for 254,922 shares at $4.03 per share and purchased 861,708 additional shares (or pre-funded warrants) at the same price in a private placement.
  • Investors received new warrants covering up to 5,583,150 shares at $4.03 per share, which the release says would provide up to $22.5 million in additional proceeds if exercised.
  • The company states the transaction provides additional capital to advance mipletamig and the next-generation pipeline, helping fund continued clinical and preclinical progress.

Analysis

Aptevo's third-quarter 2026 release is primarily a clinical business update with a short financial section. The only financial figures printed are a net loss of $6.5 million for the quarter, compared with $7.5 million for the third quarter of 2025, and cash and cash equivalents of $8.3 million at September 30, 2026, compared with $9.8 million at June 30, 2026. The release does not label the net loss as GAAP or non-GAAP, so it is treated here as reported without a basis label. No revenue, operating expense, research and development, general and administrative, interest, tax or per-share figures are printed, and no income statement table appears in the document.

The balance sheet moved in two directions over the quarter. Cash fell by $1.5 million from June 30 to September 30, 2026, while the company completed an August 2026 warrant inducement and private placement with gross proceeds of approximately $4.5 million and approximately $4.1 million net of $0.4 million in issuance costs. The release does not provide quarterly cash flow, so the document does not show how much of the decline came from operations versus other items. The filing also discloses warrants for 254,922 shares exercised at $4.03, 861,708 shares or pre-funded warrants purchased at the same price, and new warrants covering up to 5,583,150 shares at $4.03 that would provide up to $22.5 million if exercised. The up to $22.5 million figure is a contingent amount and is not part of cash on the balance sheet.

On the clinical side, the company reports a 79% CR/CRi rate in 14 evaluable TP53-mutated patients treated with mipletamig, venetoclax and azacitidine. The release compares this with a 41% composite remission rate from a published benchmark for venetoclax plus azacitidine alone, and it cites the source. It also reports that ten of 47 evaluable frontline patients proceeded to allogeneic stem cell transplantation, and that a refined priming-dose regimen reduced infusion-related reactions. These are company-reported interim results. The release's forward-looking statements caution that further assessment of preliminary or interim data may produce different results in later trials.

The release gives no revenue, segment, guidance or prior outlook, so there is no basis in this document for a comparison against expectations. The milestones it names are RAINIER Phase 1b dose optimization completion by year-end 2026, regulatory interaction for mipletamig in the first half of 2027, and IND-enabling studies for the APVO451 and radiopharmaceutical programs in 2027. The verdict is mixed: the lower net loss and the clinical updates are set against a lower cash balance, a financing that nets roughly $4.1 million, and no disclosed cash runway.

Management, verbatim

We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline.

Jeff Lamothe, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Total revenue or collaboration revenue for Q3 2026 and prior periods
  • Research and development expense, general and administrative expense and total operating expenses
  • Operating loss, interest income or expense, income tax, and per-share net loss (GAAP or otherwise)
  • Basis (GAAP or non-GAAP) of the reported net loss
  • Prior-quarter net loss (June 30, 2026 quarter) and any year-over-year or quarter-over-quarter percentage change in net loss
  • Cash and cash equivalents as of September 30, 2025, needed for a year-over-year cash comparison
  • Operating cash flow, investing cash flow, and free cash flow for the quarter
  • Total assets, total liabilities, stockholders' equity and total debt
  • Cash runway or going-concern disclosure
  • Financial guidance or previous outlook, so no comparison against prior guidance is possible
  • Segment or product-level financial data

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Aptevo Therapeutics (NASDAQ:APVO) filed an 8‑K detailing Q3 2026 results, clinical outcomes for mipletamig, and a $4.5 M warrant‑induced financing.

Company-level read

Ticker impact

$APVOBullishHigh confidence
Context

SEC 8‑K reports 79% remission rate for mipletamig in TP53‑mutated AML and $4.5M financing, first public disclosure of these results.

Expected impact

potential upside as investors price in high remission rates and additional capital.

Evidence & confidence

First‑time release of pivotal trial data and fresh funding typically drives buying pressure in biotech stocks.

Market effects

Positive AML trial data may lift other biotech firms developing multispecific immunotherapies.

Limited to US biotech sector; no broader regional effect.

Modest, confined to specialty oncology investors worldwide.

Counterpoint

Remission data from a small patient cohort may not translate to larger trials; caution on over‑optimism.

Key entities

  • Aptevo Therapeutics Inc.

    Clinical‑stage biotech developing multispecific immuno‑oncology therapeutics.

Every APVO earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$APVOHighAI 8/10

Aptevo reports Q3 results, mipletamig AML trial data

Aptevo Therapeutics (APVO) reported a Q3 2026 net loss of $6.5M, down from $7.5M in Q3 2025. Cash reserves fell to $8.3M. The company shared positive clinical data for mipletamig in AML treatment, with 79% remission rate in a small trial. It aims to complete Phase 1b trials by year-end and plans regulatory interaction in early 2027. Aptevo raised $4.5M in August via warrant inducement and private placement.

$APVOHighAI 8/10

Aptevo 3Q 2026: EPS ($5.19) — 10-Q Summary

Aptevo reported a wider net loss for 3Q 2026, driven by a $2.8M deemed dividend and lower expenses. EPS loss narrowed to $5.19 vs. $40.13 YoY. Clinical progress includes 79% CR/CRi rate in AML patients and Phase 1b completion targeted for 2026. APVO451 received a $1.5M grant for IND-enabling studies.

$APVOMedAI 8/10

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity—offering potential for difficult-